APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Complement Protein C5 Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Complement Protein C5 Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 173980180328 December 2025181 pages

Choose your research edition.

Industry ResearchComplement Protein C5 Inhibitors Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Complement Protein C5 Inhibitors Industry Growth and Trends Forecast to 203297 pages · $3,450 USDMarket StructureGlobal Complement Protein C5 Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Complement Protein C5 Inhibitors Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Complement Protein C5 Inhibitors Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Complement Protein C5 Inhibitors market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Complement Protein C5 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Complement Protein C5 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Complement Protein C5 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Complement Protein C5 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Complement Protein C5 Inhibitors include UCB, Alexion Pharmaceuticals, Astellas Pharma, Regeneron Pharmaceuticals, Amgen, Roche and Samsung Bioepis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Complement Protein C5 Inhibitors market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Complement Protein C5 Inhibitors and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Complement Protein C5 Inhibitors sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Complement Protein C5 Inhibitors market size, projected growth trends, production technologies, key applications, and end-use industries.

Complement Protein C5 Inhibitors Segment by Company

UCB

Alexion Pharmaceuticals

Astellas Pharma

Regeneron Pharmaceuticals

Amgen

Roche

Samsung Bioepis

Complement Protein C5 Inhibitors Segment by Type

Subcutaneous Administration

Oral Administration

Intravenous Injection

Complement Protein C5 Inhibitors Segment by Application

Geographic Atrophy (GA)

Atypical Hemolytic Uremic Syndrome (aHUS)

Neuromyelitis Optica Spectrum Disorde (NMOSD)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Others

Complement Protein C5 Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Complement Protein C5 Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Complement Protein C5 Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Complement Protein C5 Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Complement Protein C5 Inhibitors market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Complement Protein C5 Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Complement Protein C5 Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Complement Protein C5 Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Complement Protein C5 Inhibitors Industry Trends Table 2. Complement Protein C5 Inhibitors Industry Drivers Table 3. Complement Protein C5 Inhibitors Industry Opportunities and Challenges Table 4. Complement Protein C5 Inhibitors Industry Restraints Table 5. Global Complement Protein C5 Inhibitors Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Complement Protein C5 Inhibitors Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Complement Protein C5 Inhibitors Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Complement Protein C5 Inhibitors Sales Market Share by Manufacturers Table 9. Global Complement Protein C5 Inhibitors Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Complement Protein C5 Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Complement Protein C5 Inhibitors Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Complement Protein C5 Inhibitors Manufacturers, Product Type & Application Table 13. Global Complement Protein C5 Inhibitors Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Complement Protein C5 Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Subcutaneous Administration Table 17. Major Manufacturers of Oral Administration Table 18. Major Manufacturers of Intravenous Injection Table 19. Global Complement Protein C5 Inhibitors Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Complement Protein C5 Inhibitors Sales by Type (2021-2026) & (K Units) Table 21. Global Complement Protein C5 Inhibitors Sales by Type (2027-2032) & (K Units) Table 22. Global Complement Protein C5 Inhibitors Sales Market Share by Type (2021-2026) Table 23. Global Complement Protein C5 Inhibitors Sales Market Share by Type (2027-2032) Table 24. Global Complement Protein C5 Inhibitors Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global Complement Protein C5 Inhibitors Revenue by Type (2021-2026) & (K Units) Table 26. Global Complement Protein C5 Inhibitors Revenue by Type (2027-2032) & (K Units) Table 27. Global Complement Protein C5 Inhibitors Revenue Market Share by Type (2021-2026) Table 28. Global Complement Protein C5 Inhibitors Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Geographic Atrophy (GA) Table 30. Major Manufacturers of Atypical Hemolytic Uremic Syndrome (aHUS) Table 31. Major Manufacturers of Neuromyelitis Optica Spectrum Disorde (NMOSD) Table 32. Major Manufacturers of Paroxysmal Nocturnal Hemoglobinuria (PNH) Table 33. Major Manufacturers of Others Table 34. Global Complement Protein C5 Inhibitors Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Complement Protein C5 Inhibitors Sales by Application (2021-2026) & (K Units) Table 36. Global Complement Protein C5 Inhibitors Sales by Application (2027-2032) & (K Units) Table 37. Global Complement Protein C5 Inhibitors Sales Market Share by Application (2021-2026) Table 38. Global Complement Protein C5 Inhibitors Sales Market Share by Application (2027-2032) Table 39. Global Complement Protein C5 Inhibitors Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global Complement Protein C5 Inhibitors Revenue by Application (2021-2026) & (K Units) Table 41. Global Complement Protein C5 Inhibitors Revenue by Application (2027-2032) & (K Units) Table 42. Global Complement Protein C5 Inhibitors Revenue Market Share by Application (2021-2026) Table 43. Global Complement Protein C5 Inhibitors Revenue Market Share by Application (2027-2032) Table 44. Global Complement Protein C5 Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Complement Protein C5 Inhibitors Sales by Region (2021-2026) & (K Units) Table 46. Global Complement Protein C5 Inhibitors Sales Market Share by Region (2021-2026) Table 47. Global Complement Protein C5 Inhibitors Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global Complement Protein C5 Inhibitors Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Complement Protein C5 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America Complement Protein C5 Inhibitors Sales by Country (2021-2026) & (K Units) Table 51. North America Complement Protein C5 Inhibitors Sales by Country (2027-2032) & (K Units) Table 52. Europe Complement Protein C5 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe Complement Protein C5 Inhibitors Sales by Country (2021-2026) & (K Units) Table 54. Europe Complement Protein C5 Inhibitors Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific Complement Protein C5 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific Complement Protein C5 Inhibitors Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific Complement Protein C5 Inhibitors Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa Complement Protein C5 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa Complement Protein C5 Inhibitors Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa Complement Protein C5 Inhibitors Sales by Country (2027-2032) & (K Units) Table 61. Global Complement Protein C5 Inhibitors Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Complement Protein C5 Inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Complement Protein C5 Inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Complement Protein C5 Inhibitors Revenue Market Share by Region (2021-2026) Table 65. Global Complement Protein C5 Inhibitors Revenue Market Share by Region (2027-2032) Table 66. UCB Company Information Table 67. UCB Business Overview Table 68. UCB Complement Protein C5 Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. UCB Complement Protein C5 Inhibitors Product Portfolio Table 70. UCB Recent Development Table 71. Alexion Pharmaceuticals Company Information Table 72. Alexion Pharmaceuticals Business Overview Table 73. Alexion Pharmaceuticals Complement Protein C5 Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Alexion Pharmaceuticals Complement Protein C5 Inhibitors Product Portfolio Table 75. Alexion Pharmaceuticals Recent Development Table 76. Astellas Pharma Company Information Table 77. Astellas Pharma Business Overview Table 78. Astellas Pharma Complement Protein C5 Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Astellas Pharma Complement Protein C5 Inhibitors Product Portfolio Table 80. Astellas Pharma Recent Development Table 81. Regeneron Pharmaceuticals Company Information Table 82. Regeneron Pharmaceuticals Business Overview Table 83. Regeneron Pharmaceuticals Complement Protein C5 Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Regeneron Pharmaceuticals Complement Protein C5 Inhibitors Product Portfolio Table 85. Regeneron Pharmaceuticals Recent Development Table 86. Amgen Company Information Table 87. Amgen Business Overview Table 88. Amgen Complement Protein C5 Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Amgen Complement Protein C5 Inhibitors Product Portfolio Table 90. Amgen Recent Development Table 91. Roche Company Information Table 92. Roche Business Overview Table 93. Roche Complement Protein C5 Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Roche Complement Protein C5 Inhibitors Product Portfolio Table 95. Roche Recent Development Table 96. Samsung Bioepis Company Information Table 97. Samsung Bioepis Business Overview Table 98. Samsung Bioepis Complement Protein C5 Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Samsung Bioepis Complement Protein C5 Inhibitors Product Portfolio Table 100. Samsung Bioepis Recent Development Table 101. Key Raw Materials Table 102. Raw Materials Key Suppliers Table 103. Complement Protein C5 Inhibitors Distributors List Table 104. Complement Protein C5 Inhibitors Customers List Table 105. Research Programs/Design for This Report Table 106. Authors List of This Report Table 107. Secondary Sources Table 108. Primary Sources List of Figures Figure 1. Complement Protein C5 Inhibitors Product Image Figure 2. Global Complement Protein C5 Inhibitors Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Complement Protein C5 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 4. Global Complement Protein C5 Inhibitors Sales (2021-2032) & (K Units) Figure 5. Global Complement Protein C5 Inhibitors Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Complement Protein C5 Inhibitors Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Subcutaneous Administration Image Figure 9. Oral Administration Image Figure 10. Intravenous Injection Image Figure 11. Global Complement Protein C5 Inhibitors Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Complement Protein C5 Inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Complement Protein C5 Inhibitors Sales Market Share by Type (2021-2032) Figure 14. Global Complement Protein C5 Inhibitors Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Complement Protein C5 Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Complement Protein C5 Inhibitors Revenue Market Share by Type (2021-2032) Figure 17. Geographic Atrophy (GA) Image Figure 18. Atypical Hemolytic Uremic Syndrome (aHUS) Image Figure 19. Neuromyelitis Optica Spectrum Disorde (NMOSD) Image Figure 20. Paroxysmal Nocturnal Hemoglobinuria (PNH) Image Figure 21. Others Image Figure 22. Global Complement Protein C5 Inhibitors Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Complement Protein C5 Inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Complement Protein C5 Inhibitors Sales Market Share by Application (2021-2032) Figure 25. Global Complement Protein C5 Inhibitors Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Complement Protein C5 Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Complement Protein C5 Inhibitors Revenue Market Share by Application (2021-2032) Figure 28. North America Complement Protein C5 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America Complement Protein C5 Inhibitors Sales Market Share by Country (2021-2032) Figure 30. U.S. Complement Protein C5 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada Complement Protein C5 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico Complement Protein C5 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Complement Protein C5 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Complement Protein C5 Inhibitors Sales Market Share by Country (2021-2032) Figure 35. Germany Complement Protein C5 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France Complement Protein C5 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. Complement Protein C5 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy Complement Protein C5 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands Complement Protein C5 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Complement Protein C5 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Complement Protein C5 Inhibitors Sales Market Share by Country (2021-2032) Figure 42. China Complement Protein C5 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan Complement Protein C5 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea Complement Protein C5 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia Complement Protein C5 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India Complement Protein C5 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia Complement Protein C5 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Complement Protein C5 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Complement Protein C5 Inhibitors Sales Market Share by Country (2021-2032) Figure 50. Brazil Complement Protein C5 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa Complement Protein C5 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia Complement Protein C5 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey Complement Protein C5 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina Complement Protein C5 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE Complement Protein C5 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt Complement Protein C5 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile Complement Protein C5 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global Complement Protein C5 Inhibitors Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Complement Protein C5 Inhibitors Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Complement Protein C5 Inhibitors Revenue (2021-2032) & (US$ Million) Figure 61. North America Complement Protein C5 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Complement Protein C5 Inhibitors Revenue (2021-2032) & (US$ Million) Figure 63. Europe Complement Protein C5 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Complement Protein C5 Inhibitors Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Complement Protein C5 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Complement Protein C5 Inhibitors Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Complement Protein C5 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Complement Protein C5 Inhibitors Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Complement Protein C5 Inhibitors Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Subcutaneous Administration
  • Oral Administration
  • Intravenous Injection
Applications
  • Geographic Atrophy (GA)
  • Atypical Hemolytic Uremic Syndrome (aHUS)
  • Neuromyelitis Optica Spectrum Disorde (NMOSD)
  • Paroxysmal Nocturnal Hemoglobinuria (PNH)
  • Others
Companies covered
  • UCB
  • Alexion Pharmaceuticals
  • Astellas Pharma
  • Regeneron Pharmaceuticals
  • Amgen
  • Roche
  • Samsung Bioepis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Complement Protein C5 Inhibitors Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Complement Protein C5 Inhibitors Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Complement Protein C5 Inhibitors Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Complement Protein C5 Inhibitors Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Complement Protein C5 Inhibitors Market Dynamics
  1. 2.1 Complement Protein C5 Inhibitors Industry Trends
  2. 2.2 Complement Protein C5 Inhibitors Industry Drivers
  3. 2.3 Complement Protein C5 Inhibitors Industry Opportunities and Challenges
  4. 2.4 Complement Protein C5 Inhibitors Industry Restraints
3 Complement Protein C5 Inhibitors Market by Manufacturers
  1. 3.1 Global Complement Protein C5 Inhibitors Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Complement Protein C5 Inhibitors Sales by Manufacturers (2021-2026)
  3. 3.3 Global Complement Protein C5 Inhibitors Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Complement Protein C5 Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Complement Protein C5 Inhibitors Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Complement Protein C5 Inhibitors Manufacturers, Product Type & Application
  7. 3.7 Global Complement Protein C5 Inhibitors Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Complement Protein C5 Inhibitors Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Complement Protein C5 Inhibitors Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Complement Protein C5 Inhibitors Tier 1, Tier 2, and Tier 3
4 Complement Protein C5 Inhibitors Market by Type
  1. 4.1 Complement Protein C5 Inhibitors Type Introduction
  2. 4.1.1 Subcutaneous Administration
  3. 4.1.2 Oral Administration
  4. 4.1.3 Intravenous Injection
  5. 4.2 Global Complement Protein C5 Inhibitors Sales by Type
  6. 4.2.1 Global Complement Protein C5 Inhibitors Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Complement Protein C5 Inhibitors Sales by Type (2021-2032)
  8. 4.2.3 Global Complement Protein C5 Inhibitors Sales Market Share by Type (2021-2032)
  9. 4.3 Global Complement Protein C5 Inhibitors Revenue by Type
  10. 4.3.1 Global Complement Protein C5 Inhibitors Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Complement Protein C5 Inhibitors Revenue by Type (2021-2032)
  12. 4.3.3 Global Complement Protein C5 Inhibitors Revenue Market Share by Type (2021-2032)
5 Complement Protein C5 Inhibitors Market by Application
  1. 5.1 Complement Protein C5 Inhibitors Application Introduction
  2. 5.1.1 Geographic Atrophy (GA)
  3. 5.1.2 Atypical Hemolytic Uremic Syndrome (aHUS)
  4. 5.1.3 Neuromyelitis Optica Spectrum Disorde (NMOSD)
  5. 5.1.4 Paroxysmal Nocturnal Hemoglobinuria (PNH)
  6. 5.1.5 Others
  7. 5.2 Global Complement Protein C5 Inhibitors Sales by Application
  8. 5.2.1 Global Complement Protein C5 Inhibitors Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Complement Protein C5 Inhibitors Sales by Application (2021-2032)
  10. 5.2.3 Global Complement Protein C5 Inhibitors Sales Market Share by Application (2021-2032)
  11. 5.3 Global Complement Protein C5 Inhibitors Revenue by Application
  12. 5.3.1 Global Complement Protein C5 Inhibitors Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Complement Protein C5 Inhibitors Revenue by Application (2021-2032)
  14. 5.3.3 Global Complement Protein C5 Inhibitors Revenue Market Share by Application (2021-2032)
6 Global Complement Protein C5 Inhibitors Sales by Region
  1. 6.1 Global Complement Protein C5 Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Complement Protein C5 Inhibitors Sales by Region (2021-2032)
  3. 6.2.1 Global Complement Protein C5 Inhibitors Sales by Region (2021-2026)
  4. 6.2.2 Global Complement Protein C5 Inhibitors Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Complement Protein C5 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Complement Protein C5 Inhibitors Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Complement Protein C5 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Complement Protein C5 Inhibitors Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Complement Protein C5 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Complement Protein C5 Inhibitors Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Complement Protein C5 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Complement Protein C5 Inhibitors Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Complement Protein C5 Inhibitors Revenue by Region
  1. 7.1 Global Complement Protein C5 Inhibitors Revenue by Region
  2. 7.1.1 Global Complement Protein C5 Inhibitors Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Complement Protein C5 Inhibitors Revenue by Region (2021-2026)
  4. 7.1.3 Global Complement Protein C5 Inhibitors Revenue by Region (2027-2032)
  5. 7.1.4 Global Complement Protein C5 Inhibitors Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Complement Protein C5 Inhibitors Revenue (2021-2032)
  8. 7.2.2 North America Complement Protein C5 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Complement Protein C5 Inhibitors Revenue (2021-2032)
  11. 7.3.2 Europe Complement Protein C5 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Complement Protein C5 Inhibitors Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Complement Protein C5 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Complement Protein C5 Inhibitors Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Complement Protein C5 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 UCB
  2. 8.1.1 UCB Company Information
  3. 8.1.2 UCB Business Overview
  4. 8.1.3 UCB Complement Protein C5 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 UCB Complement Protein C5 Inhibitors Product Portfolio
  6. 8.1.5 UCB Recent Developments
  7. 8.2 Alexion Pharmaceuticals
  8. 8.2.1 Alexion Pharmaceuticals Company Information
  9. 8.2.2 Alexion Pharmaceuticals Business Overview
  10. 8.2.3 Alexion Pharmaceuticals Complement Protein C5 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Alexion Pharmaceuticals Complement Protein C5 Inhibitors Product Portfolio
  12. 8.2.5 Alexion Pharmaceuticals Recent Developments
  13. 8.3 Astellas Pharma
  14. 8.3.1 Astellas Pharma Company Information
  15. 8.3.2 Astellas Pharma Business Overview
  16. 8.3.3 Astellas Pharma Complement Protein C5 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Astellas Pharma Complement Protein C5 Inhibitors Product Portfolio
  18. 8.3.5 Astellas Pharma Recent Developments
  19. 8.4 Regeneron Pharmaceuticals
  20. 8.4.1 Regeneron Pharmaceuticals Company Information
  21. 8.4.2 Regeneron Pharmaceuticals Business Overview
  22. 8.4.3 Regeneron Pharmaceuticals Complement Protein C5 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Regeneron Pharmaceuticals Complement Protein C5 Inhibitors Product Portfolio
  24. 8.4.5 Regeneron Pharmaceuticals Recent Developments
  25. 8.5 Amgen
  26. 8.5.1 Amgen Company Information
  27. 8.5.2 Amgen Business Overview
  28. 8.5.3 Amgen Complement Protein C5 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Amgen Complement Protein C5 Inhibitors Product Portfolio
  30. 8.5.5 Amgen Recent Developments
  31. 8.6 Roche
  32. 8.6.1 Roche Company Information
  33. 8.6.2 Roche Business Overview
  34. 8.6.3 Roche Complement Protein C5 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Roche Complement Protein C5 Inhibitors Product Portfolio
  36. 8.6.5 Roche Recent Developments
  37. 8.7 Samsung Bioepis
  38. 8.7.1 Samsung Bioepis Company Information
  39. 8.7.2 Samsung Bioepis Business Overview
  40. 8.7.3 Samsung Bioepis Complement Protein C5 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Samsung Bioepis Complement Protein C5 Inhibitors Product Portfolio
  42. 8.7.5 Samsung Bioepis Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Complement Protein C5 Inhibitors Value Chain Analysis
  2. 9.1.1 Complement Protein C5 Inhibitors Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Complement Protein C5 Inhibitors Production Mode & Process
  6. 9.2 Complement Protein C5 Inhibitors Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Complement Protein C5 Inhibitors Distributors
  9. 9.2.3 Complement Protein C5 Inhibitors Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst